Kalydeco

The European Commission has approved Kalydeco ( Ivacaftor ) for people with cystic fibrosis ages 6 and older who have...


Kalydeco ( Ivacaftor ) is the first medicine to treat the underlying cause of cystic fibrosis in people with specific...


Ivacaftor ( Kalydeco ) has shown a clinical benefit in patients with cystic fibrosis who have the G551D-CFTR mutation and...